|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
ABSTRACT |
|---|
|
|
|---|
Disease severity varies among cystic fibrosis (CF) patients carrying the same cystic fibrosis transmembrane conductance regulator (CFTR) genotype and among organs of the same individual. It has been
shown that the class V splicing mutation 3849 + 10 kb C
T produces both normal and aberrantly
spliced CFTR transcripts. We analyzed the levels of normal CFTR messenger RNA (mRNA) in different
organs of an aborted fetus carrying the 3849 + 10 kb C
T mutation, and found that they correlated
with the histopathologic changes observed in these organs. We performed semiquantitative nondifferential reverse transcription-polymerase chain reaction on several organs from a 22-wk aborted CF
fetus carrying the 3849 + 10 kb C
T mutation. A very low level (1%) of normal CFTR mRNA was detected in the severely affected ileum of this fetus. Higher levels were found in the histopathologically
unaffected trachea (17%), colon (19%), and lung (26%). Thus, as early as in utero, the regulation of
alternative splice-site selection is an important mechanism underlying variable CF severity. Understanding of the mechanisms regulating alternative splicing in different tissues will contribute to potential therapy for patients carrying splicing mutations in CF and other human disease genes.
| |
INTRODUCTION |
|---|
|
|
|---|
Cystic fibrosis (CF) is caused by defects in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a cyclic adenosine monophosphate (cAMP)-regulated chloride channel (1). CF is characterized by chronic pulmonary disease, pancreatic exocrine insufficiency (PI), male infertility, and increased concentrations of electrolytes in sweat (1). However, there is wide variability in its mode of presentation, organ involvement, and severity (1). The CFTR gene is expressed in utero (2), and some of the clinical symptoms of CF may present already at birth. Almost all males with CF are infertile because of congenital bilateral absence of the vas deferens (CBAVD). Approximately 15% of CF patients are born with meconium ileus, and in some cases this may be evident in utero (1). PI may also present at birth or develop during the first weeks of life.
Genotype-phenotype studies have shown that genetic factors can affect the degree of disease expression in CF. There are mutations associated with PI and a severe form of the disease; other mutations are associated with pancreatic sufficiency (PS) and a milder form of the disease. Some mutations are associated with variable clinical presentation in all clinical parameters (5). It has been shown that different mutations in CF can be classified on the basis of defects in protein production and function (1, 5). Class V mutations affect the levels of messenger RNA (mRNA) transcripts and protein. This class of mutations includes mutations that affect correct splicing of the CFTR gene before mRNA transcription, by exon skipping or inclusion of cryptic exon(s). One example of a class V mutation, the 5T mutation, can lead to the skipping of exon 9 (6- 8). In males carrying the 5T mutation who have CBAVD but normal lung function, higher levels of normal CFTR transcripts were found in nasal epithelia than in epididymal samples, suggesting an inverse correlation between the level of normal CFTR transcripts and disease severity in these organs (6).
Class V includes another mutation, 3849 + 10 kb C
T,
which is generally associated with a milder CF phenotype,
characterized by PS in more than 60% of affected patients, as
well as by intermediate or normal sweat chloride levels, a later
age of diagnosis, and occasionally male fertility (9, 10). Despite the tendency toward an overall milder phenotype, there
is a marked variability in the severity of disease presentation
among patients and among different organs of the same patient carrying the 3849 + 10 kb C
T mutation. This mutation
creates a partially active splice site in intron 19 of the CFTR
gene, which can lead to the insertion of a new 84-bp "exon,"
harboring an in-frame stop codon, between exons 19 and 20 (9). The aim of the present study was to investigate whether
there is variability in the level of correctly and aberrantly spliced CFTR mRNA among different fetal organs carrying
the 3849 + 10 kb C
T mutation, and whether this variability
is associated with histopathologic expression of the disease.
| |
METHODS |
|---|
|
|
|---|
Fetal samples
After parental decision for elective termination of the pregnancy, tissues from an aborted fetus with the 3849 + 10 kb C
T mutation in
the CFTR gene were immediately received, dissected, and processed
for examination. Histologic inspections and RNA analysis were performed on lung, trachea, colon, ileum, pancreas, and heart tissues of
the 22-wk CF fetus. The tissues were obtained with approval of the
Human Research Committee of Brigham and Women's Hospital (Boston, MA).
RNA Extraction and Single-Strand cDNA Synthesis
RNA was extracted from the fetal tissues through the guanidinium thiocyanate method and was purified by centrifugation through a CsCl cushion (11). Complementary DNA (cDNA) was synthesized according to a previously described method (6).
Nondifferential Polymerase Chain Reactions
CFTR cDNA was amplified through the polymerase chain reaction
(PCR), using recombinant Taq DNA polymerase (Boehringer Mannheim). A nondifferential PCR reaction was designed in which the two
reverse transcription (RT)-PCR products (from the correctly and aberrantly spliced transcripts) were of the same size (524 bp and 526 bp, respectively) (Figure 1A). The oligonucleotide primers used in the
nondifferential PCR reactions permitted amplification of the cDNA
region between exon 17b and either the 19/20 junction or the 19/84-bp
junction, consisting of 17b 5'-GGACGGCAGCCTTACT TTGAA- 3' in both reactions, and p19/20 5'-AAGAGGCCCACCCTCTGGC-3' for the amplification of the normal transcript or p19/84 5'-GATGACAAGTCAACCTC TGGC-3' for the amplification of the aberrantly spliced transcript. The underlined nucleotides are common to
both primers. Reactions in which RNA was not added were used as
controls. The cDNA samples were heated at 94° C for 3 min and then
subjected to 35 cycles of denaturation at 94° C for 1 min, 57° C for 30 s,
and 65° C for 1 min, followed by final extension for 7 min at 65° C. Amplification of human
-actin was done with rat primers having the
following base sequences (which are homologous to the human sequences): 822(+) 5'-GAAACAACATACAATTCCATCATGAAGTGTGAC-3' and 996(-) 5'-AGGAGCGATAATCTTGATCTTCATGGTGCT-3'.
|
Differential PCR
A differential PCR reaction was designed in which the RT-PCR products from the correctly and aberrantly spliced transcripts were of 402 bp and 486 bp, respectively. The oligonucleotide primers used in the differential PCR reactions were C1-1D and X21A (12). The cDNA samples were heated at 94° C for 3 min and then subjected to 35 cycles of PCR at 94° C for 1 min, 50° C for 30 s, and 65° C for 1 min, followed by final extension for 7 min at 65° C.
Semiquantitative RT-PCR
Semiquantitative PCR conditions were established by RT of 2.5 µg of RNA from the lung of the embryo. PCR was then performed on each of six serial tertiary dilutions of the initial RT product (see the previous discussion). The relative intensities of the RT-PCR products for each dilution were measured with a Phosphorimager (Molecular Dynamics, Sunnyvale, CA). The range for which the results reflected the initial relative amounts of normal and aberrantly spliced transcripts was determined. Only results in the linear quantitative range were considered in any of the PCR systems (Figure 1B).
Hybridization to RT-PCR Products
Electrophoresis was done on 40 µl of each RT-PCR reaction on 1% agarose gels, with subsequent blotting. Hybridizations were done with exon 19-specific oligonucleotide primers that identified both the normally and aberrantly spliced transcripts; C1-1D (12) for the nondifferential RT-PCR and F2R (13) for the differential RT-PCR. The filters were hybridized at 37° C in buffer containing 50% formamide. The blots were washed twice in 5× standard saline citrate (SSC) at room temperature for 15 min each, followed by two washes in 2× SSC at 42° C (for the nondifferential RT-PCR) and at 54° C (for the differential RT-PCR) for 15 min each. The relative intensities of the PCR products were measured with a Phosphorimager.
| |
RESULTS AND DISCUSSION |
|---|
|
|
|---|
Routine second trimester ultrasonography revealed an echogenic
bowel in the fetus under study. CFTR mutation analysis of
the parents revealed that the mother carried the 3849 + 10 kb
C
T mutation and the father carried the
F508 mutation.
The
F508 allele leads to nonfunctional CFTR protein and is
associated with severe CF (1). Analysis of amniotic fetal
cells showed that the fetus was compound heterozygous for
the
F508 and the 3849 + 10 kb C
T mutations. The parents
elected to terminate the pregnancy. Gross inspection analysis
of organs usually affected in CF showed that the distal small
bowel (ileum) had markedly dilated, thin-walled segments alternating with regions of narrow diameter and thick walls. The
lumen was filled with abnormally thick, sticky, dark green
meconium (Figure 2). The colon was also filled with meconium. The lungs, trachea, spleen, heart, liver, kidneys, adrenal
glands, and stomach appeared normal. Histologic analysis
showed that the ileum was dilated and filled with proteinaceous material. The external diameter of the small bowel was
abnormally large and the villi were flattened, suggesting distension resulting from an obstruction. The colon, lung, liver,
heart, spleen, kidney, adrenal, stomach, and gall bladder had
normal architecture when examined light-microscopically.
|
The 3849 + 10 kb C
T mutation is generally associated
with a mild CF phenotype (9, 10), including a high rate of PS, absence of meconium ileus, and a better nutritional status.
This is the first report of severe intrauterine gastrointestinal
involvement associated with the 3849 + 10 kb C
T mutation,
presenting as meconium ileus with severe histopathologic abnormalities of the ileum. Thus, the nature of gastrointestinal
disease might vary among patients carrying the 3849 + 10 kb
C
T mutation.
The 3849 + 10 kb C
T allele was inherited by the fetus
from his Ashkenazi Jewish mother. We have previously shown
that all 3849 + 10 kb C
T alleles of Jewish origin carry the
same extended haplotype and do not carry an additional
CFTR mutation (14). Thus, correctly spliced RNA transcribed
from the 3849 + 10 kb C
T allele carried by Jewish individuals is normal CFTR mRNA that is expected to produce a
functional CFTR protein. The studied fetus was compound
heterozygous, with 3849 + 10 kb C
T/
F508, and normal
transcripts producing functional CFTR protein could only
have been those that were transcribed from the 3849 + 10 kb
C
T allele and correctly spliced. The
F508 allele produces correctly spliced RNA, although it leads to a nonfunctional
protein. If we assume that the 3849 + 10 kb C
T and
F508
alleles are transcribed at equal rates, then the amount of normal CFTR mRNA expected to yield a functional protein (i.e.,
the correctly spliced mRNA from the 3849 + 10 kb C
T allele) is equal to 50% of the total CFTR mRNA minus the aberrantly spliced RNA transcribed from the 3849 + 10 kb C
T
allele. However, we could not exclude the possibility that
F508 and the 3849 + 10 kb C
T mutation are transcribed at
different efficiencies with different promoters. In addition, the
relative stabilities of the
F508 and the 3849 + 10 kb C
T
transcripts were measured in the embryo lung sample by RT-
PCR, and were found to be similar (data not shown).
The level of normal RNA transcribed from the 3849 + 10 kb C
T allele (as a percent of the total CFTR mRNA) was
analyzed through semiquantitative, nondifferential RT-PCR
(Figure 1). To verify the specificity of the primers (p19/84 and
p19/20 for the aberrantly and correctly spliced RNAs, respectively), we amplified samples from three individuals with CF
who do not carry the 3849 + 10 kb C
T mutation. Following
hybridization with a specific probe for exon 19, C1-1D, RT-
PCR products were detected only in reactions run with the
p19/20 primer (data not shown). An alternative system, differential RT-PCR, was used to confirm that the partial differences between the p19/20 and p19/84 primers did not introduce a bias. In this reaction the PCR products differed only by
84 bp (20%), and therefore no preferential amplification was
expected. The levels of aberrantly spliced RNA (as a percent
of total CFTR mRNA) transcribed from the 3849 + 10 kb
C
T allele in four individuals compound heterozygous for
the 3849 + 10 kb C
T mutation and another CF mutation
were 0%, 9%, 22%, and 46% in the nondifferential RT-PCR system, as compared with 0%, 8.5%, 23%, and 48%, respectively, with the differential RT-PCR system. Thus, our nondifferential RT-PCR system is a suitable system for analyzing
the levels of correctly and aberrantly spliced RNA transcribed
from the 3849 + 10 kb C
T allele. Six different organs of the
fetus were analyzed: lung, trachea, pancreas, ileum, colon, and
heart (for each organ the analysis was repeated at least twice).
The analysis revealed considerable variability among the different tissues in the levels of correctly and aberrantly spliced
CFTR mRNA (Figure 3). As expected, neither normal nor aberrantly spliced CFTR transcripts could be detected in the
heart. A control PCR reaction for the
-actin gene indicated
that the heart sample had RNA in both PCR reactions (data
not shown). Among the other organs expected to transcribe the CFTR gene, the levels of normal CFTR mRNA (as a percent of the total) were variable, ranging from 1% to 26% (Table 1 and Figure 4). These results show for the first time that
there is variability in the level of correctly spliced CFTR
mRNA transcribed from the 3849 + 10 kb C
T mutation
among different organs of the same individual, and that this
variability already exists in utero. It is important to note that
our analysis was done on organs of a 22-wk fetus. Alternative
splicing is a dynamically regulated mechanism than might
change during the developmental period and might therefore
lead to changes in the relative levels of aberrantly spliced transcripts. Furthermore, our results show that variability in the
level of correctly spliced CFTR mRNA includes the gastrointestinal system, in addition to the variability between the respiratory and genital systems, as previously identified (6).
|
|
|
We further investigated the relevance of this variability to
disease expression. Our RNA analysis showed that only 1% of
the total CFTR mRNA in the ileum was normal. The other
99% of CFTR transcripts were defective owing either to the
F508 mutation or to the additional cryptic exon in aberrantly
spliced 3849 + 10 kb C
T transcripts. Thus, the severe phenotype of ileal disease, which is a consequence of primary intestinal involvement by CF (15, 16), is associated with low levels of normal CFTR mRNA in utero.
All CF patients born with meconium ileus develop PI. Thus, it is reasonable to assume that the fetus that we studied would have developed PI. Unfortunately, no histopathologic analysis of the pancreas was available to us, and as a result, the significance of the very low levels (2%) of normal CFTR mRNA in the pancreas is not clear, although it might indicate that the pancreas of the fetus was affected. The colon had a relatively higher level of normal CFTR mRNA (19%), and histopathologic analysis showed that the colon was normal.
In CF, respiratory disease usually does not present during
the neonatal period (1). Thus, normal histopathologic findings were expected for the fetal respiratory tissues (lung and trachea). Barker and colleagues (17) measured the transepithelial potential difference in monolayer preparations derived
from the lung acini of the same fetus used in our study. Their
analysis revealed cAMP-sensitive Cl
secretory responses
similar to those seen in normal fetal lung, suggesting that the
CFTR function in the lung of this fetus was normal. In accordance with these results, higher levels of normal CFTR
mRNA were identified in the respiratory tissues of the fetus (17% in the trachea and 26% in the lung).
The CF-affected organs analyzed in our study are usually
not available for study, either from patients or from fetuses.
Therefore, although we investigated only one fetus with CF,
the results are important for understanding the molecular basis for disease of differing severity in different organs of the
same patient carrying the 3849 + 10 kb C
T mutation. Overall, the levels of normal CFTR mRNA detected in the different fetal organs appeared to correlate with the histopathologic
observations on these organs (Table 1). Those organs (colon,
trachea, lung) that had no histopathologic abnormalities had
higher levels of normal CFTR mRNA, whereas the severely
affected ileum had a very low level of normal CFTR mRNA. This is in accordance with the inverse correlation found between disease severity in cells from the respiratory and the
male genital systems and the level of RNA in these systems
(6). However, in the present study, we show that the low level
of normal CFTR mRNA correlates with severe gastrointestinal disease already in utero.
Alternative splicing is a complex regulatory mechanism involving cis- and trans-acting factors. The variable levels of correctly spliced RNA transcribed from the 3849 + 10 kb C
T
allele in different organs of the same fetus are obviously not
associated with variability in cis elements. Therefore, the variability might be associated with trans-acting factors involved
in regulation of the alternative splicing mechanism. Variability
among different tissues in the relative amounts of alternative
splicing factors (18, 19) and/or tissue-specific alternative splicing factors probably contributes to the different patterns of alternative splicing found among different organs of the same
individual. Other nongenetic factors, such as viral infections
or environmental factors, might also be involved. We cannot,
however, exclude the possibility that the different levels of
correctly and aberrantly spliced CFTR transcripts among the
different organs in cases of CF result from differences in the
rates of degradation of CFTR mRNA.
In summary, alternative splicing regulation might contribute to the variability in organ involvement and expression of CF and a broad range of other inherited human diseases caused by splicing mutations. Further understanding of the mechanisms regulating alternative splicing will contribute to potential treatment for patients carrying such splicing mutations.
| |
Footnotes |
|---|
Correspondence and requests for reprints should be addressed to Batsheva Kerem, Ph.D., Department of Genetics, The Life Sciences Institute, The Hebrew University, Jerusalem, Israel 91904. E-mail: kerem@.
(Received in original form August 6, 1998 and in revised form November 6, 1998).
Dr. Kerem was supported by grants from the North American Cystic Fibrosis Foundation and the March of Dimes research Foundation. Dr. Parad was supported by grant DK2273 from the National Institutes of Health.| |
References |
|---|
|
|
|---|
1. Welsh, M. J., L.-C. Tsui, T. F. Boat, and A. L. Beaudet. 1995. Cystic fibrosis. In C.L. Scriver, A.L. Beaudet, W.S. Sly, and D. Valle, editors. The Metabolic Basis of Inherited Disease, 7th ed. McGraw-Hill, New York. 3799-3876.
2. Harris, A., G. Chalkley, S. Goodman, and L. Coleman. 1991. Expression of the cystic fibrosis gene in human development. Development 113: 305-310 [Abstract].
3.
Tizzano, E. F.,
D. Chitayat, and
M. Buchwald.
1993.
Cell-specific localization of CFTR RNA shows developmentally regulated expression in
human fetal tissues.
Hum. Mol. Genet.
2:
219-224
4.
Trezise, A. E. O.,
J. A. Chambers,
C. J. Wardle,
S. Gould, and
A. Harris.
1993.
Expression of the cystic fibrosis gene in human fetal tissues.
Hum. Mol. Genet.
2:
213-218
5. Kerem, B., and E. Kerem. 1996. The molecular basis for disease variability in cystic fibrosis. Eur. J. Hum. Genet. 4: 65-73 [Medline].
6. Rave-Harel, N., E. Kerem, M. Nissin-Rafinia, I. Madjar, R. Goshen, A. Augarten, A. Rahat, A. Hurwitz, A. Darvasi, and B. Kerem. 1997. The molecular basis of partial penetrance of splicing mutations in cystic fibrosis. Am. J. Hum. Genet. 60: 87-94 [Medline].
7.
Teng, H.,
M. Jorissen,
H. Van Poppel,
E. Legius,
J. J. Cassiman, and
H. Cuppens.
1997.
Increased proportion of exon 9 alternatively spliced
CFTR transcripts in vas deferens compared with nasal epithelial cells.
Hum. Mol. Genet.
6:
85-90
8.
Mak, V.,
K. A. Jarvi,
J. Zielenski,
P. Durie, and
L. C. Tsui.
1997.
Higher
proportion of intact exon 9 CFTR mRNA in nasal epithelium compared with vas deferens.
Hum. Mol. Genet.
6:
2099-2107
9.
Highsmith, W. E.,
L. H. Burch,
Z. Zhou,
J. C. Olsen,
T. E. Boat,
A. Spock,
J. D. Gorvoy,
L. Quittell,
K. J. Friedman,
L. M. Silverman,
R. C. Boucher, and
M. R. Knowles.
1994.
A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat
chloride concentrations.
N. Engl. J. Med.
331:
974-998
10.
Augarten, A.,
B. Kerem,
Y. Yahav,
S. Noiman,
Y. Rivlin,
A. Tal,
H. Blau,
L. Ben-Tur,
A. Szeinberg,
E. Kerem, and
E. Gazit.
1993.
Mild
cystic fibrosis and normal or borderline sweat test in patients with the
3849+10 kb C
T mutation.
Lancet
342:
25-26
[Medline].
11. Chirgwin, J. M., A. E. Przbyla, R. J. MacDonald, and W. Rutter. 1979. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18: 5294-5299 [Medline].
12.
Shoshani, T.,
E. Kerem,
A. Szeinberg,
A. Augarten,
Y. Yahav,
D. Cohen,
J. Rivlin,
A. Tal, and
B. Kerem.
1994.
Similar levels of mRNA
from the W1282X and the
F508 cystic fibrosis alleles, in nasal epithelial cells.
J. Clin. Invest.
93:
1502-1507
.
13. Chalkley, G., and A. Harris. 1991. Lymphocyte mRNA as a source for detection of mutations and polymorphism in the CF gene. J. Med. Genet. 28: 777-780.
14. Sereth, H., T. Shoshani, N. Bashan, and B. Kerem. 1993. Extended haplotype analysis of cystic fibrosis mutations and its implications for the selective advantage hypothesis. Hum. Genet. 92: 289-295 [Medline].
15. Allan, J. L., M. Robbie, P. D. Phelan, and D. U. Danks. 1981. Familial occurrence of meconium ileus. Eur. J. Pediatr. 135: 291-292 [Medline].
16.
Snouwaert, J. N.,
K. K. Brigman,
A. M. Latour,
N. N. Malouf,
R. C. Boucher,
O. Smithies, and
B. H. Koller.
1992.
An animal model for
cystic fibrosis made by gene targeting.
Science
257:
1083-1088
17. Barker, P. M., D. G. Bosworth, R. C. Boucher, and J. R. Yankaskas. 1996. Ion and liquid transport by distal lung epithelia from a F508/ 3849+10 kb human fetus. Pediatr. Pulmonol. S13: 234 .
18.
Caceres, J. F.,
S. Stamm,
D. M. Helfman, and
A. R. Krainer.
1994.
Regulation of alternative splicing in vivo by overexpression of antagonistic
splicing factors.
Science
265:
1706-1709
19.
Zahler, A. M.,
K. M. Neugebauer,
W. S. Lane, and
M. B. Roth.
1993.
Distinct functions of SR proteins in alternative pre-mRNA splicing.
Science
260:
219-222
This article has been cited by other articles:
![]() |
F Stanke, M Ballmann, I Bronsveld, T Dork, S Gallati, U Laabs, N Derichs, M Ritzka, H-G Posselt, H K Harms, et al. Diversity of the basic defect of homozygous CFTR mutation genotypes in humans J. Med. Genet., January 1, 2008; 45(1): 47 - 54. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Radpour, H. Gourabi, M. A. S. Gilani, and A. V. Dizaj Molecular Study of (TG)m(T)n Polymorphisms in Iranian Males With Congenital Bilateral Absence of the Vas Deferens J Androl, July 1, 2007; 28(4): 541 - 547. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Aznarez, E. M. Chan, J. Zielenski, B. J. Blencowe, and L.-C. Tsui Characterization of disease-associated mutations affecting an exonic splicing enhancer and two cryptic splice sites in exon 13 of the cystic fibrosis transmembrane conductance regulator gene Hum. Mol. Genet., August 15, 2003; 12(16): 2031 - 2040. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Pagani, C. Stuani, M. Tzetis, E. Kanavakis, A. Efthymiadou, S. Doudounakis, T. Casals, and F. E. Baralle New type of disease causing mutations: the example of the composite exonic regulatory elements of splicing in CFTR exon 12 Hum. Mol. Genet., May 15, 2003; 12(10): 1111 - 1120. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nissim-Rafinia, O. Chiba-Falek, G. Sharon, A. Boss, and B. Kerem Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations Hum. Mol. Genet., July 22, 2000; 9(12): 1771 - 1778. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Cell Mol. Biol. |